Subcutaneous · GLP-1 / GIP / glucagon triple
UBT251
8 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
8
Active
6
Recruiting
3
Completed
2
Sites
9
Countries
3
Endpoints
100
Composite endpoints
1
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 2
5
Phase 3
3
Trials by status
Not yet recruiting
3
Recruiting
3
Completed
2
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Weight & body composition
23
Glycemic / diabetes
21
Cardiometabolic biomarkers
15
MASH / liver
13
Safety / tolerability / PK
11
Other (unclassified)
9
Renal / kidney
5
Patient-reported / QoL
3
Most-measured metrics
Top 20 metrics across this asset's endpoints
HbA1c, changeGlycemic
2
Fasting glucose, changeGlycemic
2
Postprandial glucoseGlycemic
1
Body weight, absolute change (kg)Weight
1
Waist circumference, changeWeight
1
HbA1c <7.0% achievementGlycemic
1
HbA1c <6.5% achievementGlycemic
1
Systolic BP, changeBiomarker
1
Diastolic BP, changeBiomarker
1
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
8 of 8